This is a 30-month double-blind, randomized, Phase II platform trial designed to accelerate testing of promising investigational therapies that target tau, a key driver of Alzheimer’s disease.
The purpose of the ATP Study is to evaluate whether investigational treatments targeting tau, alone or with an amyloid-lowering treatment, can slow early changes associated with Alzheimer’s disease.
The participants in this study must be between the ages of 50-80 with either no symptoms or mild symptoms of Alzheimer’s disease. Participants must have a study partner, who has at least weekly contact with them, who can accompany them to some study visits. Participants should be willing to complete all study procedures such a blood test and brain imaging.
Interested participants can contact the Memory and Aging Program Outreach Team at (401) 455-6402 or by sending an email to memory@butler.org to discuss additional eligibility criteria.